Matthew A Pappas1,2, Geoffrey D Barnes3, Sandeep Vijan4. 1. Center for Value-Based Care Research, Medicine Institute , Cleveland Clinic, Cleveland, OH, USA. pappasm@ccf.org. 2. Department of Hospital Medicine, Medicine Institute , Cleveland Clinic, Cleveland, OH, USA. pappasm@ccf.org. 3. Frankel Cardiovascular Center, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA. 4. Division of General Internal Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Bridging anticoagulation is commonly prescribed to patients with atrial fibrillation during initiation and interruption of warfarin. Guidelines recommend bridging patients at high risk of stroke, while a recent randomized trial demonstrated overall harm in a population at comparatively low risk of ischemic stroke. Theory suggests that patients at high risk of stroke and low risk of hemorrhage may benefit from bridging, but data informing patient selection are scant. OBJECTIVE: To estimate the utility and cost-effectiveness of bridging anticoagulation among patients with nonvalvular atrial fibrillation, stratified by thromboembolic and hemorrhagic risk DESIGN: Cost-effectiveness analysis with lifelong time horizon, from the perspective of a third-party payer MAIN MEASURES: Quality-adjusted life years (QALYs) per bridged patient; US dollars per QALY gained KEY RESULTS: Unselected patients with nonvalvular atrial fibrillation may be harmed by bridging anticoagulation. Hospital admission for bridging is almost never cost-effective, and generally harmful. Among patients carefully selected by both thromboembolic and hemorrhagic risks, outpatient bridging can be beneficial and cost-effective. Results were sensitive to how effectively heparin products reduce stroke risk. CONCLUSIONS: Outpatient bridging anticoagulation can be beneficial and cost-effective for a subset of patients with nonvalvular atrial fibrillation during interruption or initiation of warfarin. Admission for bridging should be avoided.
BACKGROUND: Bridging anticoagulation is commonly prescribed to patients with atrial fibrillation during initiation and interruption of warfarin. Guidelines recommend bridging patients at high risk of stroke, while a recent randomized trial demonstrated overall harm in a population at comparatively low risk of ischemic stroke. Theory suggests that patients at high risk of stroke and low risk of hemorrhage may benefit from bridging, but data informing patient selection are scant. OBJECTIVE: To estimate the utility and cost-effectiveness of bridging anticoagulation among patients with nonvalvular atrial fibrillation, stratified by thromboembolic and hemorrhagic risk DESIGN: Cost-effectiveness analysis with lifelong time horizon, from the perspective of a third-party payer MAIN MEASURES: Quality-adjusted life years (QALYs) per bridged patient; US dollars per QALY gained KEY RESULTS: Unselected patients with nonvalvular atrial fibrillation may be harmed by bridging anticoagulation. Hospital admission for bridging is almost never cost-effective, and generally harmful. Among patients carefully selected by both thromboembolic and hemorrhagic risks, outpatient bridging can be beneficial and cost-effective. Results were sensitive to how effectively heparin products reduce stroke risk. CONCLUSIONS:Outpatient bridging anticoagulation can be beneficial and cost-effective for a subset of patients with nonvalvular atrial fibrillation during interruption or initiation of warfarin. Admission for bridging should be avoided.
Entities:
Keywords:
Monte Carlo method; anticoagulants; atrial fibrillation; models, statistical; thromboembolism
Authors: Margaret C Fang; Alan S Go; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Daniel E Singer Journal: Am J Med Date: 2007-05-24 Impact factor: 4.965
Authors: Eric E Smith; Nandavar Shobha; David Dai; Daiwai M Olson; Mathew J Reeves; Jeffrey L Saver; Adrian F Hernandez; Eric D Peterson; Gregg C Fonarow; Lee H Schwamm Journal: Circulation Date: 2010-09-27 Impact factor: 29.690
Authors: Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford Journal: Am Heart J Date: 2006-03 Impact factor: 4.749
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Jacek A Kopec; Philippe Finès; Douglas G Manuel; David L Buckeridge; William M Flanagan; Jillian Oderkirk; Michal Abrahamowicz; Samuel Harper; Behnam Sharif; Anya Okhmatovskaia; Eric C Sayre; M Mushfiqur Rahman; Michael C Wolfson Journal: BMC Public Health Date: 2010-11-18 Impact factor: 3.295
Authors: Ma Victoria Cuevas; Ignacio Martínez-Sancho; Jana Arribas; Covadonga García-Díaz; Beatriz Cuevas Journal: BMC Health Serv Res Date: 2019-11-06 Impact factor: 2.655